|
CUL5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.89768209427166E-14 |
| Normal-vs-Stage2 |
1.43630000004613E-07 |
| Normal-vs-Stage3 |
1.4432899320127E-14 |
| Normal-vs-Stage4 |
1.64734892393881E-12 |
| Stage1-vs-Stage2 |
7.493800E-01 |
| Stage1-vs-Stage3 |
4.783600E-02 |
| Stage1-vs-Stage4 |
2.959500E-03 |
| Stage2-vs-Stage3 |
1.118640E-01 |
| Stage2-vs-Stage4 |
1.039790E-02 |
| Stage3-vs-Stage4 |
1.789380E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.224680E-04 |
| Normal-vs-Asian |
3.94150045934794E-10 |
| Caucasian-vs-AfricanAmerican |
1.897800E-01 |
| Caucasian-vs-Asian |
9.861200E-01 |
| AfricanAmerican-vs-Asian |
2.519400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.44089209850063E-16 |
| Normal-vs-Female |
1.62758695410048E-12 |
| Male-vs-Female |
1.112440E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.3021363421426E-12 |
| Normal-vs-Age(41-60Yrs) |
1.99840144432528E-15 |
| Normal-vs-Age(61-80Yrs) |
3.07298630985997E-12 |
| Normal-vs-Age(81-100Yrs) |
3.437500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.373830E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.381200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.172800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.444400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.395200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.257800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.564600E-03 |
| Classical-VS-Follicular |
4.186800E-01 |
| Classical-VS-Other |
2.347600E-01 |
| Classical-VS-Normal |
1.62525548574877E-12 |
| Tall-VS-Follicular |
4.836800E-03 |
| Tall-VS-Other |
9.873000E-01 |
| Tall-VS-Normal |
9.72999458781487E-13 |
| Follicular-VS-Other |
2.260200E-01 |
| Follicular-VS-Normal |
6.10549999446874E-08 |
| Other-VS-Normal |
1.644310E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.58282325818982E-14 |
| Normal-vs-N1 |
4.77029526990691E-12 |
| N0-vs-N1 |
1.041430E-01 |
|
|
